際際滷

際際滷Share a Scribd company logo
速
VEEDA LARGE
MOLECULES
CAPABILITIES AND
EXPERIENCE
Biosimilar Analytical  Experiences/ Capabilities:
展 Completed Enoxaparin PD end point and
Immunogenicity studies (03 studies for US FDA, 01
study each for EU and ANVISA).
展 Pharmacodynamic endpoint-Anti-Xa detection and
Anti-IIa detection using Chromogenic method.
展 Immunogenicity-Anti heparin PF4 screening assay &
Total Ig GAM screening assay using ELISA technique.
展 TFPI detection using ELISA technique, Linearity range:
0.050 IU/mL to 0.200 IU/mL.
展 Heparin Clotting assay Coagulation method, Linearity
range: 0.100 IU/mL to 1.00 IU/mL.
展 IgG, IgA & IgM Screening assay using ELISA technique.
展 Total no of sample Analyzed
PK-14784, PD-3866 & Immunogenicity  3783 samples.
Large Molecules by LC/MS/MS:
Human insulin (Method Under Optimization stage):
Method under development, approach is to have intact molecule
analyzed in MS (SH-8060) (As multiple charged molecule MRM).
Proposed Linearity Range- 50 pg/mL  10000 pg/mL.
The other analogs of insulin (Glargine, aspart are also
planned to develop).
Why partner with Veeda?
展 Experienced technical staff for handling different Bioanalytical
issues.
展 Variety of Mass platform (from sub ng to sub pg level) to handle
different molecules.
展 Privately owned company with no con鍖ict of interest.
展 Assured Business Continuity.
+91 79 3001 3000 info@veedacr.com www.veedacr.com
Recent Experience of Large Molecules by Ligand binding assay:
Veeda has recently developed and validated below large molecules as per current EMEA guidance using commercially available kits by ELISA
technique of G-CSF, Insulin Aspart, C  Peptide, using validated methods study samples were analyzed as below:
Sr. No. Analyte
No. of Samples
Analyzed
No. of Samples
Analyzed for ISR
% of ISR Samples
within Acceptance
1
2
3
G-CSF 2142 158 98.7%
Insulin Aspart 2139 158 94.9%
C- Peptide 2400 176 98.2%

More Related Content

large molecule studies

  • 2. Biosimilar Analytical Experiences/ Capabilities: 展 Completed Enoxaparin PD end point and Immunogenicity studies (03 studies for US FDA, 01 study each for EU and ANVISA). 展 Pharmacodynamic endpoint-Anti-Xa detection and Anti-IIa detection using Chromogenic method. 展 Immunogenicity-Anti heparin PF4 screening assay & Total Ig GAM screening assay using ELISA technique. 展 TFPI detection using ELISA technique, Linearity range: 0.050 IU/mL to 0.200 IU/mL. 展 Heparin Clotting assay Coagulation method, Linearity range: 0.100 IU/mL to 1.00 IU/mL. 展 IgG, IgA & IgM Screening assay using ELISA technique. 展 Total no of sample Analyzed PK-14784, PD-3866 & Immunogenicity 3783 samples. Large Molecules by LC/MS/MS: Human insulin (Method Under Optimization stage): Method under development, approach is to have intact molecule analyzed in MS (SH-8060) (As multiple charged molecule MRM). Proposed Linearity Range- 50 pg/mL 10000 pg/mL. The other analogs of insulin (Glargine, aspart are also planned to develop). Why partner with Veeda? 展 Experienced technical staff for handling different Bioanalytical issues. 展 Variety of Mass platform (from sub ng to sub pg level) to handle different molecules. 展 Privately owned company with no con鍖ict of interest. 展 Assured Business Continuity. +91 79 3001 3000 info@veedacr.com www.veedacr.com Recent Experience of Large Molecules by Ligand binding assay: Veeda has recently developed and validated below large molecules as per current EMEA guidance using commercially available kits by ELISA technique of G-CSF, Insulin Aspart, C Peptide, using validated methods study samples were analyzed as below: Sr. No. Analyte No. of Samples Analyzed No. of Samples Analyzed for ISR % of ISR Samples within Acceptance 1 2 3 G-CSF 2142 158 98.7% Insulin Aspart 2139 158 94.9% C- Peptide 2400 176 98.2%